For example, if a patient maintains stable weight reduction for a year but then loses more weight after 6 months on the same GLP-1RA dose, secondary causes should be investigated, especially due to a higher malignancy risk in patients with obesity
careful riskbenefit assessment is warranted Those with pre-existing gallbladder disease : Rapid weight loss can precipitate gallstone formation or worsen existing biliary conditions People with severe gastrointestinal disease, including gastroparesis : GLP-1 receptor agonists slow gastric emptying, which may worsen symptoms in those with pre-existing gastric motility disorders Older adults : Age-related changes in renal and hepatic function may affect drug metabolism and increase sensitivity to side effects
The plastic in syringes is not designed for preserving peptide stability over many days, and there is a higher risk of contamination
Furthermore, in a meta-analysis study, a moderate increase in the relative risk and a slight increase in absolute risk of thyroid cancer with the use of GLP-1 agonists was reported 48
5 Lower doses: Eight in ten real-world patients were on maintenance doses below 1.7 mg of semaglutide or 10 mg of tirzepatide